{"filings":[{"id":90800,"accession_number":"0001493152-26-014637","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics sues investor for failing to close $3M financing","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit March 30, 2026 against an institutional investor for breach of the Securities Purchase Agreement.","Investor failed to fund $3,000,000 investment for 12,000,000 shares and 7,000,000 warrants at $0.25 per share.","Company attempted to secure funds without litigation before initiating the suit.","Additional details on the litigation to be provided in a subsequent Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90799,"accession_number":"0001493152-26-014517","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics provides update on itraconazole PK study; plans global patent filing for amorphous formulation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Top-line PK results from three-way crossover study expected after May 1, 2026; Periods 2 and 3 scheduled for April 10 and 24.","Study is the final clinical study before NDA submission to FDA under 505(b)(2) pathway for Gorlin Syndrome BCCNS.","New global patent application planned for proprietary amorphous itraconazole formulation; owned by Inhibitor with no royalty obligations.","Amorphous formulation aims to enhance solubility and absorption vs. crystalline itraconazole to address variable exposure.","Study conducted with Avior Bio in Malaysia; advancing on planned timelines and budget."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100606,"accession_number":"0001493152-26-007821","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.","Investor receives warrants to purchase up to 7,000,000 shares at $0.35/share, exercisable for 3 years.","Proceeds from the private placement will be used for working capital and general corporate purposes.","Shares and warrant shares are subject to a 9-month lock-up agreement that restricts resale.","Closing has not yet occurred; expected within a reasonable time after the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116920,"accession_number":"0001493152-25-019381","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.","Performance-based compensation includes up to 18 million unvested 4-year warrants, vesting upon milestones such as FDA approval or sale of program.","First SOW involves re-analysis of HP2001 clinical study data and preparing FDA meeting request (Type B/C/D).","Board adopted 2025 Equity Incentive Plan reserving 20 million shares; subject to shareholder approval within 12 months.","Consulting agreement continues indefinitely; each project governed by separate SOWs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}